Immune Treatment for Breast Cancer: What’s the Future?

Autologous tumour

Autologous tumour

CONTACT US

Introduction

2003–2013, a valuable study: Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage IV breast cancer.

Methodology

Dendritic cells (DCs) and cytokine-induced killer (CIK) cells have both shown activity as immunotherapy in some malignancies. Our aim was to prospective assess the effect of this immunotherapy in patients with stage IV breast cancer.

Conclusion

This research indicates that the combination of DC vaccine and CIK therapy can significantly improve DFS and OS in patients with stage IV breast cancer who only rely on chemother- apy. There is no doubt that DC CIK is a boon to stage IV breast cancer patients.  

Article Reference link: click here

Scientific article publishing date : 24/1/2017

Immucura identifier : BSC21_008EN

ALL SCIENTIFIC PAPERS
CONTACT US